How is cidofovir administered for cutaneous applications?

Label:chem

Topic
Various administration routes for cidofovir, including topical, intralesional, and intravenous methods.
Answer
Cidofovir can be administered in several ways for cutaneous applications:
Topical: Commonly compounded as a 0.5% to 3% formulation in cream, ointment, or gel. It is applied daily or twice daily for at least 1 week up to 52 weeks.
Intralesional (IL): Diluted to concentrations ranging from 2.5 mg/mL to 37.5 mg/mL (most commonly 15 mg/mL) and injected directly into the lesion using serial puncture or crosshatching techniques.
Intravenous (IV): Used in cases of extensive disease or critical illness, with dosages ranging from 3.5 to 5 mg/kg, often administered with probenecid to reduce nephrotoxicity.
Return to Home Chemical List
Knowledge you may be interested in
What is the mechanism of action of cidofovir in treating viral infections? What were the key findings from the binding affinity and functional activity assays of the synthesized naltrindole (NTI) derivatives? What is the impact of the S=O moiety in sulfonamide-type naltrindole (NTI) derivatives on their functional activities? How do the binding affinities and functional activities of the synthesized naltrindole (NTI) derivatives compare among different substituents? What is the significance of the N-substituent in the functional activities of naltrindole (NTI) derivatives for the δ opioid receptor (DOR)? How does Zileuton influence the adaptive immune response in the spleen during MHV-3 infection? How does Zileuton impact cardiopulmonary function in MHV-3-infected mice? What are the effects of Zileuton on cytokine levels and immune cell profiles in the lungs of MHV-3-infected mice? How does Zileuton affect survival and clinical outcomes in a mouse model of severe acute respiratory syndrome (SARS) caused by mouse hepatitis virus (MHV-3)? What is the role of Zileuton in modulating immune responses during coronavirus infection? What are the common side effects of cidofovir when used topically and intralesionally? What are the clinical outcomes of using cidofovir for treating verruca vulgaris and verruca plana? How effective is cidofovir in treating molluscum contagiosum? What is the role of Combretastatin A4 (CA-4) in modulating oxidative stress in human peripheral blood mononuclear cells (PBMCs)? How does Combretastatin A4 (CA-4) affect the viability and metabolic activity of human PBMCs compared to cancer cell lines? What is the impact of Combretastatin A4 (CA-4) on DNA damage in human PBMCs under oxidative stress conditions? How does Combretastatin A4 (CA-4) influence the production of reactive oxygen species (ROS) in PBMCs exposed to oxidative stress? What are the potential therapeutic implications of Combretastatin A4 (CA-4) based on its selective cytotoxicity and antioxidant properties? What are the environmental risks associated with fipronil (FIP) and imidacloprid (IMID) used in pet ectoparasiticides? How do FIP and IMID affect marine organisms?